PERSPECTA

News from every angle

← Back to headlines

Guggenheim Raises Price Target for Arcutis Biotherapeutics to $35

Guggenheim has increased its price target for Arcutis Biotherapeutics, Inc. (ARQT) to $35, maintaining a Buy rating for the biopharmaceutical company.

6 Mar, 15:20 — 6 Mar, 15:20
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual174d ago

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Read full article →

Related Stories

TotalEnergies Completes Exit From Sanctioned Russian LNG Project

32m ago

SpaceX Unveils $100 Billion Plan for New Louisiana Spaceport

48m ago

Dollar General and Dollar Tree Report Divergent Second-Quarter Earnings

54m ago

Major Canadian Banks Report Strong Third-Quarter Earnings

1h ago